Oct 29, 2026 earnings call — Proposed Trivium deal and strong quarterly results
Adjusted EPS of $1.31 this quarter, driven by segment EBIT and lower interest expense.
Revenue $2.0B (est $2.1B) · EPS $1.31 (est $1.25)
Key quotes
"With the proposed acquisition of Trivium expected to close mid-2027, our focus in the first half of the year will be on continuing to deliver on these strategic initiatives, planning for the integration and preparing the businesses for success under the new operating structure."
"While cost inflation remained a headwind in the third quarter and the pass-through mechanisms in this business tend to lag slightly longer than in our other businesses, we successfully implemented actions to recover cost increases during the third and fourth quarters that will help offset much of the impact."
"In Dispensing and Specialty Closures, we delivered another strong quarter of mid-single-digit growth for our high-end fragrance products, and our prescription pharma dispensing products continue to gain traction in the marketplace, and grew by a double-digit percentage in North America."
Analyst Q&A 11
consumer weakness in food and beverage
Q (Ghansham Panjabi · Baird): He asked what is incrementally weaker in Consumer Packaging and what customers say about strategies to offset that into 2027.
A: Management said weakness continues mainly in food and beverage, home care and lawn and garden as consumers try to stretch dollars. They noted pockets of strength in wet pet food, fragrance and prescription pharma. They said strategic initiatives are driving volume growth in other parts of the portfolio.
"But I think we feel really good about the strategic initiatives that we have that are driving volume growth through other pockets of the portfolio." — Adam Greenlee (CEO)
DSC margins, volumes, Brazil, Trivium costs
Q (George Staphos · BofA): He asked whether DSC margins will stabilize in 4Q and whether Q4 organic EBIT will be up year-over-year; he also asked what changed in volumes and for updates on Brazil and Trivium-related investment sizing.
A: Management said Q4 DSC will show year-over-year organic EBIT growth driven by pass-through recovery and strong fragrance and pharma performance offsetting consumer weakness. They said soup volumes fell after a customer took price to recover inflation and that Brazil showed no Q3 recovery and is more a 2027 recovery. They said they have not sized Trivium-related investments yet as they are still preparing the businesses.
"Our Q4 forecast or guidance for DSC, we will see year-over-year organic EBIT growing in Q4, just to be super clear about that." — Adam Greenlee (CEO)
pharma growth and Dispensing Solutions outlook
Q (Matthew Roberts · Raymond James): He asked whether the stronger pharma dispensing in 3Q was due to earlier ramp or inventory timing and whether that pace will continue into 4Q and 2027. He also asked how Dispensing Solutions might ramp in 2027 excluding one-time impacts.
A: Management said pharma is one of the fastest-growing parts of the portfolio and some shipments were a bit ahead of plan, but Q4 strength is consistent with Q3. They said they will not provide 2027 growth guidance, but overall they expect Dispensing Solutions to show higher growth over time because the segment will focus more on fragrance, beauty and healthcare.
"Number one, we're not providing growth for '27, but I think we can talk broadly about the longer-term view of these products in particular." — Adam Greenlee (CEO)
free cash flow and resin pass-through timing
Q (Jeffrey Zekauskas · JPMorgan): He asked whether free cash flow in 2027 would grow minimally or meaningfully, and whether higher propylene and polyethylene prices are felt in 4Q or 1Q given recovery timing.
A: Management said they expect free cash flow growth in 2027 but are not giving specific guidance and described it as modest and driven by volume and working capital initiatives. They said their raw-material pass-throughs are disciplined; resin recovery will occur in Q4 and some longer-lag items for dispensing will bleed into Q1.
"So we are expecting growth in free cash flow in 2027, and we're not giving specific guidance on that at this point." — Shawn Fabry (CFO)
Metal Containers cost and pricing actions
Q (Bryan Burgmeier · Citi): He asked whether better price-cost in Metal Containers was due to formula pass-throughs or cost saves, how inflation impacted Metal Containers this year, and whether any catch-up into 2027 is expected. He also asked what drove the quarter beat.
A: Management said prior cost-reduction actions, including $50 million of savings and three facility closures, lowered operating costs and improved Metal Containers' cost profile. They said raw-material pass-throughs for steel and aluminum are real-time, while other manufacturing costs have a lag that will pass through into 2027. They added the quarter beat reflected resilient operations, lower corporate transaction costs and favorable interest from treasury and working capital actions.
"So you've really got those 2 things that I think are just driving a lower cost profile for our Metal Containers business, and we feel terrific about the sustainability of that." — Adam Greenlee (CEO)
contractual pass-throughs in DSC and M&A focus
Q (Michael Roxland · Truist): He asked what percent of Dispensing and Specialty Closures lacks contractual pass-throughs and what other actions they are taking to recover costs. He also asked if the company can expand in healthcare/pharma while pursuing the Trivium deal.
A: Management said the vast majority of DSC has contractual pass-throughs for raw materials; where contracts lack pass-throughs they took aggressive price actions to recover other inflation. They said Metal and Custom Containers largely have pass-throughs already. They added the holding-company structure lets them continue healthcare expansion while executing the Trivium transaction and that the deal is designed to be leverage neutral.
"So the vast majority of the business that we have in our -- certainly our Dispensing and Specialty Closures segment do have contractual pass-throughs." — Adam Greenlee (CEO)
fragrance growth and Trivium investment type
Q (Hillary Cacanando · Deutsche Bank): She asked why fragrance continues mid-single-digit growth despite softer consumers and how much is market growth versus share gains or new launches. She also asked whether incremental investment ahead of Trivium is earnings expense or capex.
A: Management said wins come from new product launches and innovation, often capturing a disproportionate share of launches rather than competing on shelf-price. They said they have line-of-sight for 2027 launches and expect mid-single-digit long-term growth in high-end fragrance. They added incremental investments ahead of Trivium will be capital spending for product and facility readiness.
"So maybe there's a new product launch today where we win 7 of the 8 sprayers that are part of a family of products that our customers are taking to the market, but that's increasing our market share." — Adam Greenlee (CEO)
DSC mix and outlook for weak parts
Q (Arun Viswanathan · RBC): He asked what percent of the DSC segment is fragrance/beauty and healthcare, and whether weaker parts could turn positive. He also asked what customers say about promotions versus price actions and how Silgan wins share.
A: Management said fragrance and beauty is less than half of the segment and closer to a third or a bit more, and healthcare is about a $250 million business. They said fragrance and healthcare growth offset food and beverage softness and they expect similar volume patterns in Q4 with continued fragrance and pharma growth but a challenged food and beverage consumer. They said customer responses vary — some use promotions, others take price to recover inflation — and the company wins through innovation and customer-focused design.
"So you're right, it is less than half on the fragrance and beauty side, it's closer to a third or a little bit more than that." — Shawn Fabry (CFO)
Custom Containers steady state and fragrance economics
Q (Anojja Shah · UBS): He asked when the Custom Containers business exit anniversaries and whether it will reach a steady state, and he asked for more detail on financial implications of winning a fragrance launch over multiyear timelines.
A: Management said the Custom Containers cost actions finished in the fourth quarter of last year and that Q4 cycles the change for the final time. They expect a steady state in 2027 and believe the business is poised for longer-term growth at the improved margin levels. On fragrance, they said mid-single-digit volume growth projections encompass the multiyear product launch visibility and more detailed financials can be discussed later.
"We finished that in the fourth quarter of last year." — Adam Greenlee (CEO)
prescription pharma size and timelines
Q (Daniel Rizzo · Jefferies): He asked what percentage of sales prescription pharma dispensing is and whether it is a multiyear regulated process before commercial results emerge.
A: Management said prescription pharma is a rapidly growing part of the portfolio and is roughly a $250 million overall business residing primarily in the Dispensing Solutions segment. They said these are regulated products with 3- to 5-year pipelines involving Drug Master Files and significant development and regulatory review, and that their approach is innovation-led rather than price-led.
"it's a rapidly growing part of our portfolio, and we've talked about it being roughly a $250 million overall business for us at Silgan, resides primarily in what will ultimately be the Dispensing Solutions segment." — Adam Greenlee (CEO)
customer pricing/promotion mix and private label
Q (George Staphos · BofA): He asked whether customers (like in soup) are beginning to pass through inflation and whether that will be a theme over the next 12 months, and he asked about the remaining self-make private label opportunity in metal markets.
A: Management said customer strategies are mixed: some customers use promotions that drive volume, and others (for example in soup) are choosing to take price to recover inflation. They said private-label self-manufacturers are performing well in food cans and represent a large presence, driven by consumers trading down.
"We have some customers and certainly some products that are continuing to focus on promotional activity, and that is driving volume growth." — Adam Greenlee (CEO)